ArticleCancer management and research2026
Machine Learning Prediction of Prolonged Length of Stay in Older Patients with Lung Cancer: A Multicenter Study Using XGBoost with SHAP Interpretation.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prolonged length of stay (PLOS) is common among older patients with lung cancer and is associated with increased risks of adverse outcomes, greater healthcare resource utilization, and reduced treatment efficiency. However, reliable risk stratification tools specifically designed for this population, particularly in the Chinese healthcare context, remain lacking. Methods: This multicenter retrospective study included patients aged 65 years or older with primary lung cancer from two Chinese hospitals. PLOS was defined as a length of stay exceeding the 75th percentile of the overall cohort. After least absolute shrinkage and selection operator‑based feature selection from 34 candidate variables, six machine learning models were developed in the training set and validated using both internal and external validation sets. Model performance was assessed using discrimination, calibration, and clinical utility metrics. The optimal model was interpreted using SHapley Additive exPlanations (SHAP). Results: A total of 5,836 patients were included. Among the six models, XGBoost achieved the highest discriminative performance, with area under the receiver operating characteristic curve values of 0.821 (95% CI: 0.806-0.837) in the training set, 0.773 in internal validation, and 0.727 in external validation. Calibration curves and decision curve analysis demonstrated satisfactory agreement and net clinical benefit. SHAP analysis identified pneumonia, hypoproteinemia, C‑reactive protein (CRP), uric acid (UA), and admission pathway as the top five predictors. Pneumonia, hypoproteinemia, CRP, admission pathway, and systolic blood pressure were positively associated with PLOS, whereas UA and total protein showed negative associations. Conclusion: The XGBoost model provided robust and generalizable predictions of PLOS in older Chinese patients with lung cancer. Its interpretability may facilitate early identification of high‑risk individuals and support targeted perioperative interventions in geriatric oncology care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.